Jay has experience in procuring patents in the mentioned fields, including matters relating to nucleotide compositions, small molecule compositions, processes and methods. In addition, he has drafted opinions relating to non-infringement and invalidity in many of those fields. He strives to have excellent rapport with clients and also to understand their business goals, whether they be large companies, start-ups, or clients of foreign law firms.
Jay also has experience managing patent portfolios. He has managed an extensive global patent portfolio for a start-up headed by a former CEO of a prominent chemical company. While working for a large Florida law firm, he was instrumental in bringing the first biotech client for that firm and effectively managing the client’s portfolio.
NEWS & PUBLICATIONS
Jay has written many articles which have been published in bar journals, industry trade journals and patent blogs. The articles include the following:
- Lessons of Wisdom Following Athena SCOTUS Denial and October 2019 Patent Eligibility Guidance Update IPWatchdog® (February 20, 2020)
- January 2019 Guidelines for evaluation of a claim as being patent-eligible subject matter: A step forward in the right direction? (June 3, 2019)
- Inherent obviousness necessitates specific motivation to modify lead compound in pharma process due to surprising, unexpected results. IPWatchdog® (August 10, 2017)
- The Scope of Prior Art Under AIA - Genetic Engineering and Biotechnology News (2013)
- Co-author, with Christopher Paradies, Ph.D., “What Measures are Reasonable for Protecting Your Client’s Secrets,” Hillsborough County Bar Association Lawyer (Vol. 16, No. 7, April 2006).
University of Wisconsin Law School, J.D.
Graduate School of Basic Medical Sciences, New York Medical College, M.S. Biochemistry & Molecular Biology
Fordham University, B.S. Biological Sciences
New York State Bar
New Jersey State Bar
Florida State Bar
U.S. Patent and Trademark Office